Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor–Associated Periodic Syndrome
Authors:
- Elizabeth DreweEDElizabeth Drewe
- Elizabeth M. McDermottEMElizabeth M. McDermott
- Richard J. PowellRPRichard J. Powell
- 5 October 2000
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (14) , 1044-1045
Abstract
The tumor necrosis factor (TNF) receptor–associated periodic syndrome is a dominantly inherited, chronic inflammatory condition characterized by lifelong febrile attacks of abdominal and musculoskeletal pain associated with skin lesions. The attacks vary in severity and in frequency, usually last from 3 to 21 days, and respond to high-dose corticosteroids. Soluble TNF receptors can inhibit TNF activity by binding and preventing the interaction of TNF-α (TNFSF2) with its cell-surface receptor. Recombinant human TNF receptor (TNFRSF1B) (p75):Fc fusion protein (etanercept) inhibits the activity of TNF in vitro and reduces inflammation in animal models.1Keywords
This publication has 5 references indexed in Scilit:
- Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory SyndromesCell, 1999
- TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide.Journal of the American Society of Nephrology, 1998
- TNF-α stimulates monocyte adhesion to glomerular mesangial cells. The role of intercellular adhesion molecule-1 gene expression and protein kinasesThe Journal of Immunology, 1996
- Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.The Journal of Immunology, 1993
- Evaluation of Systemic Amyloidosis by Scintigraphy with123I-Labeled Serum Amyloid P ComponentNew England Journal of Medicine, 1990